Patent ID: 11951127
Assignee: NEW SOUTH WALES HEALTH PATHOLOGY
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 5:
6. The composition of claim 1, comprising:
(a) a population of T cells reactive with cytomegalovirus and a population of T cells reactive with Epstein-Barr virus; or
(b) a population of T cells reactive with cytomegalovirus and a population of T cells reactive with Epstein-Barr virus and a population of T cells reactive with BK virus; or
(c) a population of T cells reactive with an extract of Candida krusei and a population of T cells reactive with an extract of Aspergillus terreus; or
(d) a population of T cells reactive with an extract of Candida krusei and a population of T cells reactive with an extract of Aspergillus terreus and a population of T cells reactive with BK virus and a population of T cells reactive with adenovirus; or
(e) a population of T cells reactive with an extract of Candida krusei and a population of T cells reactive with an extract of Aspergillus terreus and a population of T cells reactive with cytomegalovirus and a population of T cells reactive with Epstein Barr virus; or
(f) a population of T cells reactive with Wilms tumor 1 (WT-1) and a population of T cells reactive with preferentially expressed antigen in melanoma (PRAME); or
(g) a population of T cells reactive with cytomegalovirus and a population of T cells reactive with Epstein-Barr virus and a population of T cells reactive with WT-1 and a population of T cells reactive with PRAME; or
(h) a population of T cells reactive with cytomegalovirus and a population of T cells reactive with Epstein-Barr virus and a population of T cells reactive with an extract of Aspergillus terreus and a population of T cells reactive with an extract of Candida krusei and population of T cells reactive with WT-1 and a population of T cells reactive with PRAME.